The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors
Abstract
Purpose: First-in-human phase I trial to determine the safety, pharmacokinetics, and antitumor activity of BIND-014, a novel, tumor prostate-specific membrane antigen (PSMA)–targeted nanoparticle, containing docetaxel. Experimental Design: Patients with advanced solid tumors received BIND-014 every three weeks (n = 28) or weekly (n = 27), with dose levels ranging from 3.5 to 75 mg/m2 and 15 to 45 mg/m2, respectively. Results: BIND-014 was generally well tolerated, with no unexpected toxicities. The most common drug-related toxicities (>20% of patients) on either schedule included neutropenia, fatigue, anemia, alopecia, and diarrhea. BIND-014 demonstrated a dose-linear pharmacokinetic profile, distinct from docetaxel, with prolonged persistence of docetaxel-encapsulated circulating nanoparticles. Of the 52 patients evaluable for response, one had a complete response (cervical cancer on the every three week schedule) and five had partial responses (ampullary adenocarcinoma, non–small cell lung, and prostate cancers on the every-three-week schedule, and breast and gastroesophageal cancers on the weekly schedule). Responses were noted in both PSMA-detectable and -undetectable tumors. Conclusions: BIND-014 was generally well tolerated, with predictable and manageable toxicity and a unique pharmacokinetic profile compared with conventional docetaxel. Clinical activity was noted in multiple tumor types. The recommended phase II dose of BIND-014 is 60 mg/m2 every three weeks or 40 mg/m2 weekly. Clin Cancer Res; 22(13); 3157–63. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
(1997) · PubMed · Cited by 1,541
Hrkach, J., Von Hoff, D., Ali, M. M., Andrianova, E., Auer, J., Campbell, T., De Witt, D., Figa, M., Figueiredo, M., Horhota, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003651 · Cited by 1,147
Self-citationAccelerated Titration Designs for Phase I Clinical Trials in Oncology
Simon, R., Rubinstein, L., Arbuck, S. G., Christian, M. C., Freidlin, B., & Collins, J. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.15.1138 · Cited by 639
Liu, H., Moy, P., Kim, S., Xia, Y., Rajasekaran, A. K., Navarro, V., Knudsen, B., & Bander, N. H. (1997) · PubMed · Cited by 528
Prostate-specific membrane antigen is produced in tumor-associated neovasculature.
Chang, S. S., O’Keefe, D. S., Bacich, D. J., Reuter, V. E., Heston, W. D. W., & Gaudin, P. B. (1999) · PubMed · Cited by 471
Is prostate-specific membrane antigen a multifunctional protein?
Rajasekaran, A. K., Anilkumar, G., & Christiansen, J. J. (2005) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00506.2004 · Cited by 232
Docetaxel administration schedule: From fever to tears? A review of randomised studies
Engels, F. K., & Verweij, J. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.02.016 · Cited by 93
Phase II Clinical Trial of Docetaxel in Refractory Squamous Cell Carcinoma of the Cervix
García, A. A., Blessing, J. A., Vaccarello, L., & Roman, L. D. (2007) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31803377c8 · Cited by 65
Cited by
Controlled drug delivery vehicles for cancer treatment and their performance
Senapati, S., Mahanta, A. K., Kumar, S., & Maiti, P. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-017-0004-3 · Cited by 2,167
Polymeric Nanoparticles for Drug Delivery
Beach, M. A., Nayanathara, U., Gao, Y., Zhang, C., Xiong, Y., Wang, Y., & Such, G. K. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00705 · Cited by 1,155
Polylactic acid (PLA) controlled delivery carriers for biomedical applications
Tyler, B., Gullotti, D., Mangraviti, A., Utsuki, T., & Brem, H. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.018 · Cited by 1,050
Nanomedicine in cancer therapy
Fan, D., Cao, Y., Cao, M., Wang, Y., Cao, Y., & Gong, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01536-y · Cited by 878
PLGA-Based Nanoparticles in Cancer Treatment
Rezvantalab, S., Drude, N. I., Moraveji, M. K., Güvener, N., Koons, E. K., Shi, Y., Lammers, T., & Kiessling, F. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01260 · Cited by 607
Metadata
- Authors
- Von Hoff, D. D., Mita, M. M., Ramanathan, R. K., Weiss, G. J., Mita, A. C., LoRusso, P. M., Burris, H. A., Hart, L. L., Low, S. C., Parsons, D. M., Zale, S. E., Summa, J. M., Youssoufian, H., & Sachdev, J. C.
- Venue
- Clinical Cancer Research
- Published
- 2016-06-30
- Volume
- 22
- Issue
- 13
- Pages
- 3157-3163
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2252831137
- Cited by
- 286
- References
- 11
- FWCI
- 10.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-2548
- The paper
- Von Hoff, D. D., Mita, M. M., Ramanathan, R. K., Weiss, G. J., Mita, A. C., LoRusso, P. M., Burris, H. A., Hart, L. L., Low, S. C., Parsons, D. M., Zale, S. E., Summa, J. M., Youssoufian, H., & Sachdev, J. C. (2016). Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-2548
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.